EVAX News and Press, Evaxion Biotech A/S From 05/27/25

Evaxion A/S (EVAX) is expected to report $-0.65 for Q1 2025

2025-05-26 18:47:43 ET Evaxion Biotech A/S (EVAX) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 3.96%. The average open to low on the day of earnings was -6.88%. The average open to cl...

2025-05-26 18:42:45 ET Evaxion Biotech A/S (EVAX) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in EVAX stock price following earnings has averaged ±3.76% , with a median of 2.23%. ...

2025-05-26 08:47:59 ET Summary Evaxion has demonstrated impressive in-house capabilities for discovering and developing vaccine candidates for both infectious diseases and oncology indications. Partnership with MSD, albeit heavily backloaded, provides considerable validation of Ev...

COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its first quarter 2025 financial results on Tuesday, May 27, 2025...

Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data package Will provide insights into the durability of immune and clinical responses up to three years Extension ph...

80% of EVX-01 vaccine targets triggered a tumor-specific immune response, a substantially higher frequency than what has been reported for other similar vaccine candidates The data underscores the precision of Evaxion’s AI-Immunology™ platform in selecting therapeutically re...

Congress will take place April 21-24, 2025, in Washington, D.C. COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will give two prese...

2025-04-01 11:21:15 ET Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Conference Call April 01, 2025, 08:30 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rønø - Chief Scientific Officer Thomas Schmidt - Chief Financial Of...

2025-04-01 07:46:04 ET More on Evaxion Biotech ADS Evaxion Biotech stock slides after pricing $10.8M securities offering Seeking Alpha’s Quant Rating on Evaxion Biotech ADS Historical earnings data for Evaxion Biotech ADS Financial information for Evax...